Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

Robin K. Avery(Johns Hopkins University), Francisco M. Marty(Brigham and Women's Hospital), Aimee K. Sundberg(Takeda (United States)), Emily A. Blumberg(University of Pennsylvania), Catherine Cordonnier(Université Paris-Est Créteil), Diana F. Florescu(University of Nebraska Medical Center), Nassim Kamar(Centre National de la Recherche Scientifique), Martha Fournier(Takeda (United States)), Deepali Kumar(University Health Network), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Rafael F. Duarte(Institut Català d'Oncologia), Sophie Alain(Inserm), Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Johan Maertens(Unknown), Oliver Witzke(Essen University Hospital), Jingyang Wu(Leeds Teaching Hospitals NHS Trust), Barbara D. Alexander(Duke University), Fernanda P. Silveira(University of Pittsburgh Medical Center)
Clinical Infectious Diseases
December 1, 2021
Cited by 299


Related Papers